Effects of the Class III antiarrhythmic agent dofetilide (UK‐68,798) on L‐type calcium current from rabbit ventricular myocytes

The methanesulphonanilide agent dofetilide (UK‐68,798) exerts Class III antiarrhythmic effects by inhibiting the cardiac rapid delayed rectifier potassium current (IKr) encoded by HERG. The aim of the present study was to determine whether dofetilide also exhibits Class IV (L‐type calcium‐channel blocking) effects. L‐type calcium current (ICa,L) was measured from rabbit isolated ventricular myocytes, using the whole‐cell patch‐clamp technique under selective recording conditions. Positive control experiments demonstrated inhibition of ICa,L elicited by pulses to + 10 mV by both nifedipine and externally applied Ni2+ ions. Three concentrations of dofetilide were tested: 100 nm, 1 μm and 10 μm. ICa,L magnitude was not significantly reduced by any of the concentrations tested (P>0.05; n = minimum of seven cells per drug concentration). The inactivation time‐course of ICa,L was also unaffected by 10 μm dofetilide. Heterologously expressed HERG current (IHERG) recorded from Chinese Hamster Ovary cells was extensively inhibited by 100 nm and 1 μm dofetilide, with inhibition at 1 μm not significantly different from 100% (P> 0.1). It is concluded that dofetilide produced no ICa,L blocking effects at concentrations up to and exceeding that required for maximal IHERG inhibition. The findings support the notion that dofetilide is a highly selective Class III antiarrhythmic agent, devoid of Class IV antiarrhythmic activity.

[1]  M. Malik,et al.  QTc Interval as a Guide to Select Those Patients With Congestive Heart Failure and Reduced Left Ventricular Systolic Function Who Will Benefit From Antiarrhythmic Treatment With Dofetilide , 2001, Circulation.

[2]  Itsuo Kodama,et al.  Short- and Long-Term Effects of Amiodarone on the Two Components of Cardiac Delayed Rectifier K+ Current , 2001, Circulation.

[3]  M. Malik,et al.  QT Dispersion Has No Prognostic Information for Patients With Advanced Congestive Heart Failure and Reduced Left Ventricular Systolic Function , 2001, Circulation.

[4]  H. Witchel,et al.  Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. , 2001, Biochemical and biophysical research communications.

[5]  Kenneth Egstrup,et al.  Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial , 2000, The Lancet.

[6]  R. Falk,et al.  Dofetilide: a new pure class III antiarrhythmic agent. , 2000, American heart journal.

[7]  L. Køber,et al.  Dofetilide: a class III anti-arrhythmic drug for the treatment of atrial fibrillation , 2000, Expert opinion on investigational drugs.

[8]  J. Hancox,et al.  Familial And Acquired Long QT Syndrome And The Cardiac Rapid Delayed Rectifier Potassium Current , 2000, Clinical and experimental pharmacology & physiology.

[9]  J. Hancox,et al.  Inhibition by nickel of the L-type Ca channel in guinea pig ventricular myocytes and effect of internal cAMP. , 2000, American journal of physiology. Heart and circulatory physiology.

[10]  A. Pappano,et al.  Comparison of L-type calcium channel blockade by nifedipine and/or cadmium in guinea pig ventricular myocytes. , 2000, The Journal of pharmacology and experimental therapeutics.

[11]  J. Hancox,et al.  Antiarrhythmics—from cell to clinic: past, present, and future , 2000, Heart.

[12]  A. Bril,et al.  Electrophysiological characterization of BRL-32872 in canine Purkinje fiber and ventricular muscle. Effect on early after-depolarizations and repolarization dispersion. , 1999, European journal of pharmacology.

[13]  A. Camm,et al.  What Should We Expect From the Next Generation of Antiarrhythmic Drugs? , 1999, Journal of cardiovascular electrophysiology.

[14]  J. Hancox,et al.  EFFECT OF PHOSPHORYLATION ON L‐TYPE CALCIUM CURRENT IN VENTRICULAR MYOCYTES DIALYSED WITH PROTEOLYTIC ENZYMES , 1999, Clinical and experimental pharmacology & physiology.

[15]  C. January,et al.  Proarrhythmia Related to Prolongation of Repolarization: Mechanisms, Monitoring, Prevention, and Management , 1998 .

[16]  Harry J. Witchel,et al.  Time course and voltage dependence of expressed HERG current compared with native ”rapid” delayed rectifier K current during the cardiac ventricular action potential , 1998, Pflügers Archiv.

[17]  A. Bril,et al.  Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: comparison between BRL-32872 and azimilide. , 1998, Cardiovascular research.

[18]  A. Brown,et al.  Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide. , 1996, Circulation.

[19]  Bertram Pitt,et al.  Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction , 1996, The Lancet.

[20]  R. Fischmeister,et al.  Binding constants determined from Ca2+ current responses to rapid applications and washouts of nifedipine in frog cardiac myocytes. , 1996, The Journal of physiology.

[21]  D. Snyders,et al.  High affinity open channel block by dofetilide of HERG expressed in a human cell line. , 1996, Molecular pharmacology.

[22]  H. Duff,et al.  [3H]dofetilide binding: biological models that manifest solely the high or the low affinity binding site. , 1996, Journal of molecular and cellular cardiology.

[23]  R. Campbell,et al.  Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. , 1995, The American journal of cardiology.

[24]  T. Ogura,et al.  Action potentials, ionic currents and cell water in guinea pig ventricular preparations exposed to dimethyl sulfoxide. , 1995, The Journal of pharmacology and experimental therapeutics.

[25]  M. Kanno,et al.  Effects of dofetilide on membrane currents in sinoatrial node cells of rabbit. , 1995, Japanese journal of pharmacology.

[26]  G. Yellen,et al.  Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. , 1994, BioTechniques.

[27]  J. Brachmann,et al.  Differential Effects of the New Class III Agent Dofetilide on Potassium Currents in Guinea Pig Cardiomyocytes , 1994, Journal of cardiovascular pharmacology.

[28]  Jules C. Hancox,et al.  A method for isolating rabbit atrioventricular node myocytes which retain normal morphology and function. , 1993, The American journal of physiology.

[29]  M. Sanguinetti,et al.  Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. , 1993, Circulation research.

[30]  G. Butrous,et al.  Dofetilide, A Novel Class III Antiarrhythmic Agent , 1992, Journal of cardiovascular pharmacology.

[31]  Robert Lemery,et al.  Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. , 1992, The New England journal of medicine.

[32]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[33]  J. Arrowsmith,et al.  UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. , 1991, The Journal of pharmacology and experimental therapeutics.

[34]  J. Jalife,et al.  Cardiac Electrophysiology: From Cell to Bedside , 1990 .

[35]  M. Sanguinetti,et al.  Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents , 1990, The Journal of general physiology.

[36]  Craig T. January,et al.  Early Afterdepolarizations: Mechanism of Induction and Block A Role for L‐Type Ca2+ Current , 1989, Circulation research.

[37]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.